HY
Hyperfine, Inc.
HYPR · NASDAQ
$0.80 +0.75% (+$0.01)
1M -8.32%
Market Cap $67.0M
P/E Ratio -
Div. Yield -
ROE 100.30%
Bulios Fair Price
$0.53
33.4% downside
Current Price
$0.8
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HYPR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
68 /100
Cheap P/S 4.05x
P/B 1.82x
P/E N/A
Growth
78 /100
Growing Rev. growth 25.79%
Book val. growth 30.80%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 51.41%
FCF margin 166.48%
Net margin 210.75%
Quality
3 /100
Poor ROIC 62.78%
Asset turnover 0.26x
ROE 100.30%
Debt
67 /100
Low Debt/Equity 0.36x
Int. coverage -55.58x
Current ratio 6.15x
Stability
50 /100
Moderate Beta 1.41x
Profitable years 0
Rev. volatility 29.94%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HYPR
Online
Sector
Healthcare
Industry
Medical - Devices
CEO
Maria Degois Sainz
Employees
102
Headquarters
Guilford
Upcoming events
12 NOV
Earnings
Upcoming earnings report